Chronic Obstructive Lung Disease (Cold) Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease, also called COPD, is actually a group of lung diseases. People with COPD have limitations in the airflow through their airways. The limitation usually worsens over time. Lungs of people with COPD become easily inflamed from noxious particles or gases. The airways produce extra mucus, which is coughed up as sputum.

Chronic bronchitis and emphysema are two common types of COPD. Chronic bronchitis isan ongoing inflammation of the large airways. Emphysema is a chronic disease in which the tissues of the lungs are gradually destroyed.

What is going on in the body?

Chronic obstructive pulmonary disease is caused by exposure to noxious gases or particles, especially cigarette smoke. Over time, this exposure damages the airways. The airways try to protect themselves by making more mucus. However, the lungs may slowly get damaged from chronic irritation. The increased mucus and lung damage can be permanent.

The World Health Organization (WHO) has recently developed a classification system for the severity of COPD. There are four stages of severity, as outlined below:

Stage 0, or at risk for COPD. These people have chronic cough and sputum production. Their lung function tests are still normal.

Stage I, or mild COPD. Individuals in this group have mild limitations in their airflow and changes in their lung function tests. They generally have chronic cough and sputum production.

Stage II, or moderate COPD. People at this stage have worsening of airflow that leads to shortness of breath with exertion. Their lung function tests show marked limitations.

Stage III, or severe COPD. Individuals at this stage have severe airflow limitations that impair their quality of life. Their lung function tests are markedly abnormal.

What are the causes and risks of the disease?

Cigarette smoking is the most common cause of COPD. The risk goes up with the amount of tobacco smoked, and the number of years of smoking. COPD is most common in countries where smoking is prevalent. It is less common in countries where people smoke less. Passive smoking, or exposure to secondhand smoke, does increase a person’s risk for COPD.

Other risk factors for COPD include the following:

asthma

hereditary deficiency of alpha-1 antitrypsin, an enzyme involved in lung function

indoor air pollution, such as smoke from home cooking or home heating fuels

low birth weight

occupational dusts and chemicals

outdoor air pollution, such as motor vehicle exhaust fumes

severe childhood respiratory infections

What are the signs and symptoms of the disease?

Typical symptoms of COPD are cough and sputum production. Following are some other symptoms of COPD:

shortness of breath, which tends to worsen with exertion

swelling in the legs and feet

wheezing, which is a high-pitched sound made when the person breathes

How is the disease diagnosed?

Diagnosis of COPD begins with a medical history and physical examination. Lung function tests can identify COPD in Stage 0, even before the individual has symptoms. Lung function tests measure how much air a person can take in with a deep breath. They also measure how fast the person can push the air back out of the lungs. The healthcare provider may also order a chest X-ray and blood tests.

What can be done to prevent the disease?

Many risk factors for COPD can be completely eliminated. Smoking cessation is vital for those who smoke. Sources of indoor air pollution can be identified and removed. It’s important to avoid secondhand smoke.

What are the long-term effects of the disease?

COPD is the fourth leading cause of death in the world. The long-term effects depend on how severe the COPD is when diagnosed and if a reduced exposure to the lung irritant occurs. The most effective treatment is quitting smoking. This will typically result in a modest improvement or no further decline in function. People with COPD have a higher mortality than those with normal lung function. Causes of death include respiratory failure, lung infections such as pneumonia and influenza, and other diseases related to smoking. These include cancer, heart disease, and stroke.

What are the risks to others?

COPD is not contagious. However, people who live with smokers have significant health risks because of their exposure to the smoke.

What are the treatments for the disease?

WHO has identified the following four components for management of COPD:

assessing and monitoring the disease

reducing the person’s risk factors

managing stable COPD

managing exacerbations, or episodes where symptoms are worse

Assessment and monitoring

Assessment and monitoring of the disease incorporates the following steps:

identification of people at risk for COPD, even if they don’t have symptoms

performing lung function tests to measure airflow limitations

doing a medical history and physical exam to evaluate symptoms

Reducing risk factors

Reducing the person’s risk factors includes the following measures:

avoiding vigorous outdoor exercise when air quality is poor

smoking cessation, if the person smokes

limiting exposure to secondhand smoke

reducing occupational dusts and chemicals

eliminating sources of indoor pollution, such as wood-burning stoves

Managing stable COPD

Management of stable COPD includes the following:

learning to identify and avoid risk factors

learning to identify problems and seek appropriate treatment

taking medications as directed

WHO recommendations for management of COPD are broken down by the severity of the disease. Following are recommendations for Stage 0 COPD:

getting a flu vaccine once or twice a year

using antibiotics only for bacterial infections, but not for COPD itself

identifying and eliminating risk factors

Recommendations for Stage I COPD are the same as those for Stage 0. In addition, people with Stage I COPD should use short-acting bronchodilators as needed. Bronchodilators relieve cough and shortness of breath by opening the airways. In general, WHO recommends inhaled bronchodilators rather than oral medications.

Recommendations of Stage II COPD include the recommendations from Stage I. Additional measures are recommended for times when symptoms are present, including the following:

using long-acting bronchodilators on a regular basis

using inhaled glucocorticosteroids, for people with significant cough or shortness of breath

participating in a pulmonary rehabilitation program, which uses teaching and exercise to improve lung function

WHO gives the following recommendations for Stage III COPD:

using long-acting bronchodilators regularly

taking short-acting bronchodilators as needed

seeking treatment for complications, such as pneumonia

participating in a pulmonary rehabilitation program

using oxygen as needed

discussing surgical options with the healthcare provider

Managing exacerbations

People with COPD may have worsening, or exacerbation, of symptoms when they develop a respiratory infection. Symptoms may also be worsened by cigarette smoke, as well as other factors. WHO guidelines for management of exacerbations include the following:

increasing the dose and/or frequency of inhaled bronchodilators

taking oral glucocorticosteroids to decrease airway swelling

taking antibiotics for bacterial infection

taking oxygen by mask or cannula

being on a ventilator, or artificial breathing machine

What are the side effects of the treatments?

Bronchodilators may cause an increased heart rate and blood pressure. Oral glucocorticosteroids can cause increased risk for infection, high blood sugar, and osteoporosis. Antibiotics can cause rash, stomach upset, and allergic reaction.

What happens after treatment for the disease?

Early diagnosis of COPD and effective treatment can slow its progression. People who eliminate risk factors and follow treatment guidelines have better outcomes. Those who continue to smoke may be increasingly disabled by breathing problems and complications of COPD.

How is the disease monitored?

COPD is monitored through regular visits with the healthcare provider. Lung function tests can be used to monitor limitations in airflow. Any new or worsening symptoms should be reported to the healthcare provider.